Skip to main content

ALGN Q2 Deep Dive: Tariffs, Consumer Caution, and Restructuring Shape Outlook

ALGN Cover Image

Dental technology company Align Technology (NASDAQ: ALGN) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 1.6% year on year to $1.01 billion. Next quarter’s revenue guidance of $975 million underwhelmed, coming in 6.4% below analysts’ estimates. Its non-GAAP profit of $2.49 per share was 3.3% below analysts’ consensus estimates.

Is now the time to buy ALGN? Find out in our full research report (it’s free).

Align Technology (ALGN) Q2 CY2025 Highlights:

  • Revenue: $1.01 billion vs analyst estimates of $1.06 billion (1.6% year-on-year decline, 4.8% miss)
  • Adjusted EPS: $2.49 vs analyst expectations of $2.57 (3.3% miss)
  • Adjusted EBITDA: $256.5 million vs analyst estimates of $267.7 million (25.3% margin, 4.2% miss)
  • Revenue Guidance for Q3 CY2025 is $975 million at the midpoint, below analyst estimates of $1.04 billion
  • Operating Margin: 16.1%, up from 14.3% in the same quarter last year
  • Sales Volumes were flat year on year (3.2% in the same quarter last year)
  • Market Capitalization: $10.18 billion

StockStory’s Take

Align Technology’s second quarter was marked by lower-than-expected revenue and profit, which led to a substantial negative market reaction. Management pointed to weaker-than-normal patient case conversion in late June, especially in North America and parts of Europe, as a key driver. CEO Joe Hogan acknowledged that “June just didn’t materialize the way we thought it would,” citing reduced patient traffic and heightened consumer reluctance to spend on elective dental procedures. Hogan also highlighted a continued shift by some orthodontists to traditional braces amid economic uncertainty, further impacting demand for clear aligners.

Looking ahead, Align Technology’s outlook is shaped by persistent macroeconomic uncertainty, ongoing tariff impacts, and evolving consumer financing challenges. Management expects continued softness in clear aligner volumes, with Hogan stating that their forecast “basically [takes] what we’ve seen in the end of the quarter and projected forward.” The company is planning operational restructuring—including streamlining its manufacturing footprint and workforce reductions—to preserve efficiency and support investments in next-generation technologies. CFO John Morici emphasized that these steps are intended to “sharpen operational focus, reduce ongoing costs and enhance capital efficiency” as Align navigates a cautious demand environment.

Key Insights from Management’s Remarks

Management emphasized that lower patient case conversion and doctor hesitancy to invest in digital tools, combined with tariffs and financing constraints, were the most significant headwinds in the quarter.

  • Case conversion fell short: Despite strong consumer interest in Invisalign, uneven patient case conversion late in the quarter—especially in North America and key European markets—resulted in lower aligner volumes than anticipated. Management attributed this to consumer hesitancy around out-of-pocket spending for elective dental care.
  • Orthodontist channel shift: Some orthodontic practices reverted to traditional wires and brackets instead of clear aligners, particularly those less committed to digital workflows. Hogan explained this as a response to inventory considerations and economic caution, impacting Align’s core growth segment.
  • Financing and tariff pressures: Both patients and doctors faced affordability challenges due to less attractive financing options and continued global tariff volatility. These external factors made practices and patients more cautious about investing in both aligners and capital equipment.
  • Scanner sales mix changed: Sales of the new iTero Lumina scanner grew mainly through upgrade wands rather than full system purchases. While management saw “good increase” in wand upgrades, overall scanner system sales lagged due to limited willingness to invest in capital equipment amid weak patient traffic.
  • Restructuring actions announced: Align plans to realign business groups, reduce its global workforce, and optimize manufacturing assets. The company expects these moves—costing up to $170 million—to deliver operational efficiencies and support long-term margin improvement.

Drivers of Future Performance

Align’s near-term outlook is shaped by continued consumer caution, evolving product mix, and cost-reduction initiatives to offset weaker demand.

  • Consumer demand uncertainty: Management expects ongoing hesitancy among patients regarding elective dental procedures, leading to modest clear aligner volume growth and a shift toward lower-priced noncomprehensive products. Hogan noted that “timing and affordability concerns are reshaping how and when [patients] choose to commit to treatment.”
  • Operational restructuring impact: Planned workforce reductions and manufacturing asset optimization are expected to lower costs and improve operating margins over time. Morici stated these actions should boost operating margin by at least 100 basis points in 2026, though near-term margins will be pressured by one-time restructuring charges.
  • Tariffs and macroeconomic headwinds: Ongoing tariff uncertainty, inflation, and elevated interest rates remain risks, impacting both pricing strategies and demand for Align’s products and services. The company is adjusting international pricing and continuing to monitor regulatory developments, particularly in the U.K. and U.S.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will closely watch (1) trends in patient conversion rates and consumer willingness to spend on elective dental procedures, (2) the effectiveness and pace of Align’s operational restructuring and cost savings, and (3) the adoption rate of new products such as the iTero Lumina scanner and recent clear aligner offerings. Continued monitoring of tariff impacts and international pricing adjustments will also be important indicators of progress.

Align Technology currently trades at $140.49, down from $204.41 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.